Your browser is no longer supported. Please, upgrade your browser.
Greenwich LifeSciences, Inc.
Index- P/E- EPS (ttm)-0.14 Insider Own17.20% Shs Outstand14.90M Perf Week-9.39%
Market Cap468.14M Forward P/E- EPS next Y-1.29 Insider Trans0.50% Shs Float2.54M Perf Month-28.20%
Income-1.90M PEG- EPS next Q-0.26 Inst Own0.90% Short Float12.48% Perf Quarter-9.41%
Sales- P/S- EPS this Y48.80% Inst Trans-0.84% Short Ratio0.48 Perf Half Y922.79%
Book/sh1.85 P/B19.41 EPS next Y-11.20% ROA-21.10% Target Price- Perf Year-
Cash/sh2.20 P/C16.31 EPS next 5Y- ROE-25.30% 52W Range3.26 - 158.07 Perf YTD-1.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.29% Beta-
Dividend %- Quick Ratio27.40 Sales past 5Y- Gross Margin- 52W Low1000.55% ATR4.60
Employees1 Current Ratio27.40 Sales Q/Q- Oper. Margin- RSI (14)48.66 Volatility6.91% 13.19%
OptionableNo Debt/Eq0.01 EPS Q/Q-174.70% Profit Margin- Rel Volume0.19 Prev Close34.09
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume665.61K Price35.90
Recom2.00 SMA20-6.57% SMA504.44% SMA20039.07% Volume127,852 Change5.31%
Apr-21-21 09:42AM  
Apr-19-21 10:30AM  
Apr-16-21 02:26AM  
Apr-14-21 06:00AM  
Apr-12-21 04:17PM  
Apr-10-21 04:13PM  
Apr-09-21 12:00PM  
Apr-02-21 08:39AM  
Mar-25-21 03:37AM  
Mar-24-21 03:39PM  
Mar-23-21 06:00AM  
Mar-22-21 12:31PM  
Mar-11-21 06:00AM  
Mar-10-21 07:59PM  
Mar-08-21 03:57PM  
Mar-02-21 06:00AM  
Feb-25-21 06:00AM  
Feb-02-21 09:41AM  
Jan-29-21 11:33AM  
Jan-21-21 06:00AM  
Jan-08-21 06:00AM  
Jan-05-21 12:52PM  
Dec-28-20 10:35AM  
Dec-25-20 02:02AM  
Dec-24-20 06:00AM  
Dec-22-20 10:12AM  
Dec-18-20 02:47PM  
Dec-16-20 02:53PM  
Dec-15-20 06:00AM  
Dec-11-20 08:00AM  
Dec-10-20 04:16PM  
Dec-09-20 02:29PM  
Dec-03-20 07:00AM  
Dec-02-20 07:00AM  
Nov-23-20 07:00AM  
Nov-18-20 07:00AM  
Nov-12-20 09:00AM  
Nov-05-20 09:00AM  
Oct-08-20 08:00AM  
Oct-07-20 08:00AM  
Oct-06-20 04:01PM  
Sep-29-20 04:17PM  
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel SnehalCEO and CFOApr 13Buy36.982,70099,8531,189,539Apr 14 07:30 AM
Hallock KennethDirectorNov 24Buy5.391,0005,386397,004Nov 27 07:00 AM
Daugherty Frank JosephChief Medical OfficerNov 23Buy5.101,0005,10087,010Nov 25 07:00 AM
Hallock KennethDirectorNov 20Buy5.371,0005,370396,004Nov 24 08:00 AM
McWilliams DavidDirectorNov 20Buy5.401,5008,100620,101Nov 24 08:00 AM
Rothe EricDirectorNov 20Buy5.402,00010,800313,226Nov 24 08:00 AM
Patel SnehalCEO and CFONov 19Buy5.402,00010,7951,186,839Nov 20 07:00 AM